Q-omics provides the consensus-scored TMEM183A profile across patient tissues and cancer cell-line models. TMEM183A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM183A is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, TMEM183A RNA expression shows 19,276 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where TMEM183A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM183A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM183A survival associations across molecular data types. TMEM183A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM183A RNA expression–survival associations across cancer types. High TMEM183A expression shows unfavorable associations in ACC, MESO, LIHC, KICH and KIRP, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM183A RNA expression.
This table summarizes TMEM183A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM183A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM183A shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, BRCA and LUSC. The LIHC box plot shows higher TMEM183A RNA expression in tumor versus normal tissue (log2 FC = +1.163, t-test p < 0.001).
This table shows molecular features associated with TMEM183A in patient tissues and cancer cell lines. In patient samples, TMEM183A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM183A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
